One of the most important tools, and perhaps one of the most confusing tools, for metallurgists is the binary phase diagram.

"FDA grants IND clearance for Innate Pharma’s solid tumour trial" was originally created and published by Clinical Trials ...

Incendia Therapeutics has enrolled the first subject in a Phase Ic clinical trial of PRTH-101, a novel DDR1 inhibitor aimed ...

Moderna's mRNA-4359 has shown early signs of efficacy, activating key proteins to trigger an immune response for cancer ...

Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced that Snapdragon Chemistry, a Cambrex company, has successfully developed a new liquid-phase ...

According to Biospace.com "The solid tumors market size reached a value of US$ 170.3 Billion in 2023. Looking forward, the market is expected to reach US$ 375.4 Billion by 2034, exhibiting a growth ...

The FDA granted fast track designation to EO-3021 for the treatment of advanced or metastatic gastric and gastroesophageal ...

Broadcom has an excellent growth runway, substantial sales and profitability growth potential, and is relatively cheap now.

Following an investigational new drug application clearance from the FDA, a phase 1 trial plans to evaluate CD-001.

Additional Phase 2 studies in solid tumors are planned to begin in 2025.” CBX-12 is designed to deliver higher concentrations of exatecan, a topoisomerase 1 (TOP1) inhibitor, directly to tumor ...

TRESR (NCT04497116) is a first-in-human, multi-center, open-label Phase 1/2 dose-escalation and expansion study ... activity associated with camonsertib monotherapy in patients with solid tumors ...

Data demonstrate broad activity of CBX-12 across six tumor types with a strong response rate in TOP1-naïve patients with ...